GlassScriptPhysician profile
Abel C Toledo
NPI 1518059799
$5,293.94
in general payments reported to CMS, 2019-2025
40 companies · $544 in 2025
The $544 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,247 · 2020: $945 · 2021: $625 · 2022: $554 · 2023: $498 · 2024: $881 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $775.03 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Mannkind Corporation | $394.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.58 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $338.59 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $329.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $310.49 | 2019-2020 | |
| Novo Nordisk INC | $259.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $254.86 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $213.03 | 2019-2022 | |
| Amarin Pharma, INC. | $190.18 | 2019-2022 | |
| Dexcom, INC. | $178.95 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $171.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.09 | 2021-2025 | |
| Heartflow, INC. | $163.01 | 2024 | |
| Amgen INC. | $136.07 | 2023-2025 | Repatha, Otezla, Repatha |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Toledo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.